Search for:

Webmail
CU Access
Canvas
Quick Links

School of Medicine

Home
Education

Admissions

Current Students

Contact Us

CUSOM LCME Accreditation
Research

Annual Campus Research Forum

Clinical Trials

Colorado Clinical & Translational Sciences Institute (CCTSI)

Research Core Labs

Health Data Compass

Information Services

Office of Grants & Contracts

Office of Laboratory Animal Resources

Regulatory Compliance

Research Affairs

Research Development

Resources for Investigators

Transformational Research Funding

Donate
Patient Care

Office of Clinical Affairs

Office of Advanced Practice

Donate
Departments | Centers | Institutes
Dean's Office

About Us

Administrative Fellowship Program

Administrative Toolbox

Alumni

Calendar

Contact Information

CU Medicine Today

The Hub

Information Services

Leadership

University of Colorado Medicine

Donate
Faculty

Home

Faculty Affairs

Faculty Development

Faculty Relations

News
News

Depemokimab Cuts Asthma Exacerbation Risk 46%: Michael Wechsler, MD

minute read

by AJMC | October 2, 2026

Michael Wechsler, MD, of National Jewish Health, discusses how twice yearly depemokimab reduces exacerbation risk in patients with T2 asthma.

Topics: Press Coverage

Spread the word:

Related Articles

School of Medicine

CU Anschutz

Fitzsimons Building

13001 East 17th Place

Aurora, CO 80045

303.724.5375

Facebook Twitter

School

School of Medicine Home

Find a Researcher

School Profiles

General

Affiliate/Partner Hospitals

Map and Parking

Students

Health Sciences Library

Colorado Springs Branch

Contact Us
Website Feedback
CU System
Privacy Policy
Terms of Use
Accessibility
Accreditation
Employment
Give Now

© 2025 The Regents of the University of Colorado, a body corporate. All rights reserved.

Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.